Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
46
SOLTF Quote, Financials, Valuation and Earnings
Last price:
$5.44
Seasonality move
:
4.99%
Day range:
$5.44 - $5.44
52-week range:
$4.90 - $7.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.47x
P/B ratio:
1.27x
Volume:
--
Avg. volume:
24
1-year change:
-16.56%
Market cap:
$492.3M
Revenue:
$198M
EPS (TTM):
-$0.92
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Nxera Pharma Co., Ltd. has -- downside to fair value with a price target of -- per share.
SOLTF vs. S&P 500
-
Over the past 5 trading days, Nxera Pharma Co., Ltd. has overperformed the S&P 500 by 1.46% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Nxera Pharma Co., Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nxera Pharma Co., Ltd. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nxera Pharma Co., Ltd. reported revenues of $50.4M.
Earnings Growth
-
Nxera Pharma Co., Ltd. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Nxera Pharma Co., Ltd. reported earnings per share of -$0.55.
Enterprise value:
728.4M
EV / Invested capital:
0.96x
Price / LTM sales:
2.47x
EV / EBIT:
--
EV / Revenue:
3.67x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-34.08x
Price / Operating cash flow:
57.47x
Enterprise value / EBITDA:
101.52x
Gross Profit (TTM):
$143.4M
Return On Assets:
-8.68%
Net Income Margin (TTM):
-41.8%
Return On Equity:
-19.06%
Return On Invested Capital:
-9.66%
Operating Margin:
-17.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $88.2M | $190.1M | $198.3M | $45M | $50.4M | |
| Gross Profit | $51M | $120.3M | $143.4M | $31M | $37.1M | |
| Operating Income | -$71.2M | -$43.8M | -$55.3M | -$18.8M | -$8.9M | |
| EBITDA | -$53.9M | -$17.5M | -$26.1M | -$12.3M | -$1.8M | |
| Diluted EPS | -$0.62 | -$0.36 | -$0.92 | -$0.10 | -$0.55 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $545.4M | $530.1M | $461.9M | $368.1M | $283.7M | |
| Total Assets | $854.6M | $759.6M | $1.1B | $964M | $859.9M | |
| Current Liabilities | $62.4M | $31M | $121.9M | $99.5M | $111.6M | |
| Total Liabilities | $355.2M | $320.5M | $641.1M | $528M | $470.8M | |
| Total Equity | $499M | $439.1M | $473.9M | $436M | $389.1M | |
| Total Debt | $254.2M | $225.4M | $523.7M | $432M | $366.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$37.7M | -$51.8M | -$17.3M | -$72.4M | -$67.5K | |
| Cash From Investing | -$441.8M | -$31.4M | $35.2M | -$32.5M | $11.7M | |
| Cash From Financing | $332.9M | -$44.6M | -$104M | -$10.3M | -$70M | |
| Free Cash Flow | -$43.7M | -$61.9M | -$21.4M | -$80M | -$1M | |
SOLTF
Sector
Market Cap
$492.3M
$24M
Price % of 52-Week High
75.56%
48.29%
Dividend Yield
0%
0%
Shareholder Yield
4.81%
-1.62%
1-Year Price Total Return
-16.56%
-22.92%
Beta (5-Year)
0.018
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.44
200-day SMA
Sell
Level
$6.01
Bollinger Bands (100)
Sell
Level
5.14 - 6.26
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$5.36
Relative Strength Index (RSI14)
Buy
Level
53.33
ADX Line
Neutral
Level
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$5.35
MACD (12, 26)
Buy
Level
1.47
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.7078)
Sell
CA Score
(Annual)
Level (-0.8725)
Buy
Beneish M-Score
(Annual)
Level (-2.2539)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.9148)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nxera Pharma Co., Ltd. is a technology powered biopharma company focused on specialty medicines in Japan and globally. The company engages in activities from discovery through to late clinical stage and commercialization, internally and in partnership with global pharma and biotech companies. It focuses on some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders, and rare diseases, and leverages the power of its GPCR targeted structure based drug discovery NxWave platform to provide a source of best- or first-in-class medicines. The company was founded by Shinichi Tamura and Takaya Nakamura on June 22, 1990 and is headquartered in Tokyo, Japan.
Stock Forecast FAQ
In the current month, SOLTF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SOLTF average analyst price target in the past 3 months is --.
-
Where Will Nxera Pharma Co., Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nxera Pharma Co., Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Nxera Pharma Co., Ltd.?
Analysts are divided on their view about Nxera Pharma Co., Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nxera Pharma Co., Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Nxera Pharma Co., Ltd.'s Price Target?
The price target for Nxera Pharma Co., Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SOLTF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nxera Pharma Co., Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SOLTF?
You can purchase shares of Nxera Pharma Co., Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nxera Pharma Co., Ltd. shares.
-
What Is The Nxera Pharma Co., Ltd. Share Price Today?
Nxera Pharma Co., Ltd. was last trading at $5.44 per share. This represents the most recent stock quote for Nxera Pharma Co., Ltd.. Yesterday, Nxera Pharma Co., Ltd. closed at $5.44 per share.
-
How To Buy Nxera Pharma Co., Ltd. Stock Online?
In order to purchase Nxera Pharma Co., Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SOLTF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SOLTF
Sector
P/E ratio
--
23.44x
PEG ratio
-0.04x
-0.01x
P/B ratio
1.27x
1.73x
Price / LTM sales
2.47x
1.51x
Growth Metrics
SOLTF
Sector
Revenue growth
12.11%
3.31%
Earnings growth
-469.03%
10.7%
Revenue (5-year growth)
19.04%
6.28%
Earnings forecast
--
-$0.19
Profitability
SOLTF
Sector
Profitability FY 2025
$143.2M
$2.6M
Return on invested capital
-9.66%
-33.62%
Return on assets
-8.68%
-29.74%
Return on equity
-19.06%
-39.33%
Earnings Date
Last Earnings Date
Feb
13
Next Earnings Date
Feb
15
Estimated Next Earnings Date
May
17
Balance Sheet
SOLTF
Sector
Total cash
$129.9M
$25M
Short term investments
$25.1M
$23.9M
Total assets
$859.9M
$71.9M
Long term debt
$366.1M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
